Accumed disputes Neopath's AutoPap patent
This article was originally published in Clinica
Accumed has filed a protest with the US Patent Office against Neopath's patent application for a method and apparatus for rapid capture of focused microscopic images on its AutoPap 300 QC system. Accumed says that it has already been using the technology behind Neopath's application in several of its own automated screening products. Accumed believes the subject matter for the application does not qualify for a patent and has requested that the patent application be re-examined. Accumed estimates that the world cytopathology market is worth $2,000 million annually.